Today: 20 May 2026
Experian share price slides in London as buyback update lands and AI disruption fears linger
6 February 2026
2 mins read

Experian share price slides in London as buyback update lands and AI disruption fears linger

LONDON, Feb 6, 2026, 08:48 GMT — Regular session

  • Experian shares dropped roughly 1.8% early Friday, giving back some of Thursday’s gains.
  • The credit-checker revealed an additional tranche of share buybacks carried out late Thursday.
  • Investors are eyeing if the recent AI-driven selloff in data and analytics stocks still has room to deepen.

Experian (EXPN) slipped 1.8% to 2,575 pence in early London trading Friday, down from Thursday’s close of 2,621 pence. The stock fluctuated between 2,560 and 2,593 pence during the session, still far off its 52-week peak of 4,101 pence.

Investors are juggling two competing factors: ongoing buybacks that bolster earnings per share, and growing questions about how fast AI innovations might undercut pricing power in data and analytics. On Thursday, Experian climbed 2.95%.

Experian revealed it snapped up 399,453 shares on the London Stock Exchange on Feb. 5, paying an average of 2,619.2358 pence each. The purchase price swung between 2,590 and 2,648 pence. Since kicking off its buyback programme, the firm has repurchased 1,647,231 shares and now holds 56,683,651 shares in treasury.

A separate filing revealed modest share buys from two board members. Chair Mike Rogers picked up 1,600 shares at 25.56 pounds each, while non-executive director Kathleen DeRose acquired 550 shares at $34.2244 apiece, the notice stated. (PDMR stands for “person discharging managerial responsibilities,” a term used in UK dealing disclosures.) Investegate

Experian revealed a fresh $1 billion share buyback plan on Jan. 30, maintaining its existing capital allocation framework and dividend policy.

This week has been tough for information and software stocks, driven by investor reaction to Anthropic’s updated chatbot and its new plug-ins, seen as potential disruptors in legal, sales, marketing, and data analysis sectors. Mike Archibald, portfolio manager at AGF Investments, told Reuters, “Sometimes the market just shoots first and asks questions later.” Reuters

Volatility is now seeping into wider positioning moves as investors wrestle with whether the selloff has run its course or is still gaining steam. “The selloff… is a manifestation of an awakening to the disruptive power of AI,” James St. Aubin, chief investment officer at Ocean Park Asset Management, told Reuters. Reuters

For Experian, the issue isn’t just one product—it’s about how resilient its data, analytics, and decisioning businesses remain as AI tools grow cheaper and more accessible. Share buybacks might ease pressure in the short run, but they don’t address the bigger risk if clients start pushing back on prices.

Friday is also the day Experian will pay its first interim dividend for 2026, set at 21.25 US cents per share. The ex-dividend date lands on Jan. 8.

Experian is set to report its full-year results for the year ending March 31, 2026, on May 20.

The downside is clear: if the market continues viewing AI as a fundamental risk to “information edge” firms, valuations might shrink faster than buybacks can support, leaving shares stuck near recent lows even as cash returns hold steady.

Traders are set to track buyback speed and pricing closely over the coming sessions. Then, all eyes turn to the May 20 earnings to spot any shifts in demand, pricing, or guidance amid the ongoing AI discussion.

Stock Market Today

  • Tesla Q1 2026 Earnings Beat; Stock Faces Mixed Outlook for 2030
    May 20, 2026, 10:24 AM EDT. Tesla (TSLA) reported Q1 2026 earnings per share (EPS) of $0.41, exceeding the $0.36 consensus, with automotive gross margin rising to 21.1% from 16.2%. Operating income increased 135.8% year-on-year (YoY), and services plus Full Self-Driving (FSD) revenue jumped 42% to $3.75 billion, with 1.28 million active FSD subscriptions up 51%. Despite strong fundamentals, Tesla shares fell 8.83% year-to-date to $409.99 amid skepticism about AI monetization and scaling autonomy. Wall Street's average target is about $412, while a proprietary model estimates a base case price of $510 by 2030, with a bull case of $645. Achieving $650 requires significant price-to-earnings multiple expansion or sharp EPS growth from AI ventures, amid challenges like increased operating expenses and production constraints.

Latest articles

POET Technologies Jumps After $400M AI Photonics Raise, Dilution Questions Linger

POET Technologies Jumps After $400M AI Photonics Raise, Dilution Questions Linger

20 May 2026
POET Technologies shares rose 11% to $14.55 in early Nasdaq trading Wednesday after closing a US$400 million direct offering of 19 million shares and warrants. The rebound followed an 8% drop Tuesday on dilution concerns. The company reported Q1 revenue of $503,389 and a net loss of $12.3 million. A recent $50 million order from Lumilens could scale to $500 million over five years if production ramps up.
Nokia’s U.S. Broadband Order Arrives While AI-Driven Gains Test Supply Chain

Nokia’s U.S. Broadband Order Arrives While AI-Driven Gains Test Supply Chain

20 May 2026
Nokia shares rose 3.37% in Helsinki trading Wednesday after the FCC conditionally approved its Beacons and ONT devices, exempting them from U.S. Covered List restrictions. Nokia also transferred 975,289 treasury shares to equity plan participants. Dell’Oro Group forecasts the optical transport equipment market will grow 16% in 2026, driven by AI data centers.
Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left

Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left

20 May 2026
Biogen completed its acquisition of Apellis Pharmaceuticals, removing APLS shares from Nasdaq and paying investors $41 per share plus a contingent value right tied to Syfovre sales. Apellis shareholders tendered 82.4% of outstanding stock before the offer expired May 13. Biogen shares rose 0.9% to $192.34 Wednesday. The CVR could pay up to $4 if Syfovre meets future sales targets.
Compass Group share price slips again as AI fears linger after Q1 update
Previous Story

Compass Group share price slips again as AI fears linger after Q1 update

Molina Healthcare stock sinks premarket after 2026 outlook miss, Medicare exit plan
Next Story

Molina Healthcare stock sinks premarket after 2026 outlook miss, Medicare exit plan

Go toTop